Health Care

Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.

Rhode Island lawmakers are considering raising the state's minimum wage again.

Shares of biotechnology companies are tumbling over price-control concerns following Democratic presidential frontrunner Hillary Clinton's statement that she will release a plan to address "price gouging" in the industry.

Analysts say they expect more tie-ups are coming in the generic drug industry in the wake of Teva's mammoth deal for the generic drug business of Allergan.

Shares of Synergy Pharmaceuticals jumped 47 percent before Wednesday's opening bell on encouraging, late-state study results for its constipation drug.

Shares of Universal Health Services fell Wednesday after the company disclosed that the U.S. government expanded its fraudulent billing investigation to include the hospital operator as a corporate entity.

Shares of ImmunoGen jumped 23 percent in premarket trading Monday after the biotechnology company signed a licensing deal with Japan's Takeda Pharmaceutical Co.

Biogen Idec released much anticipated results from a study of a potential Alzheimer's disease treatment on Friday, showing that it slowed cognitive decline in some patients.

AbbVie Inc. says it is buying leukemia drugmaker Pharmacyclics for $21 billion.

The biggest obstacle for Coca-Cola and Pepsi these days isn't tied to taste tests, the declining popularity of sugary drinks or even their century-long rivalry.

The biggest obstacle for Coca-Cola and Pepsi these days isn't tied to taste tests, the declining popularity of sugary drinks or even their century-long rivalry.

Shares of Achillion Pharmaceuticals Inc. jumped Monday morning after the drug developer said a small group of patients who took its experimental hepatitis C treatment combination remained free of the liver-destroying virus three months after they stopped taking doses.

Shares of Gilead Sciences Inc. dropped Wednesday after the drugmaker's executives discussed pricing discounts and competition facing its blockbuster hepatitis C drugs.

A 30 percent swing in a blink of an eye is not uncommon in the stock market.

Shares of Tekmira Pharmaceuticals soared Monday after the Canadian drugmaker said it would buy privately held OnCore Biopharma to form a team focused on developing a hepatitis B cure.

Pharmaceutical distributor AmerisourceBergen is spending about $2.5 billion to expand its reach into veterinary medicine with the purchase of MWI Veterinary Supply.

Shares of Cempra shot up nearly 30 percent early Monday after the antibiotic developer said its treatment for patients with a common form of pneumonia fared well in late-stage clinical testing.

Shares of ImmunoGen plunged 37 percent in premarket trading Friday after a breast cancer treatment from drug development partner Roche failed to deliver significant improvement in a key late-stage study measurement of cancer patients.

Mallinckrodt will re-evaluate its fiscal 2015 forecast after the Food and Drug Administration said it is concerned that the company's generic ADHD drug is not equivalent to the brand-name drug it is based on.

For stocks, it's just what the doctor ordered.